Loading...

FITC anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_FITC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) FITC and CD127 (clone SB/199) PE.
  • 145-2C11_FITC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) FITC and CD127 (clone SB/199) PE.
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100305 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100306 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed
  2. Bertrand F, et al. 2017. Nat Commun. 8:2256. PubMed
  3. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  4. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  5. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  6. Li DD, et al. 2022. J Cell Mol Med. 26:2438. PubMed
  7. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  8. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  9. Yang L, et al. 2023. Acta Pharmacol Sin. :. PubMed
  10. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  11. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  12. Murakata Y, et al. 2023. Front Cardiovasc Med. 9:1075358. PubMed
  13. Jerome JR, et al. 2023. Int J Mol Sci. 24: . PubMed
  14. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  15. Glorieux C, et al. 2022. J Adv Res. 40:109. PubMed
  16. Wu R, et al. 2022. Nat Immunol. 23:1536. PubMed
  17. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  18. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  19. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  20. Brunner SM, et al. 2023. Int J Mol Sci. 24:. PubMed
  21. Senatus L, et al. 2023. Commun Biol. 6:280. PubMed
  22. Stitzlein LM, et al. 2023. Front Neurol. 14:1112207. PubMed
  23. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  24. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
  25. Chei S, et al. 2020. Front Nutr. 7:583186. PubMed
  26. Schulteis R, et al. 2008. Blood. 112:4905. PubMed
  27. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  28. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
  29. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  30. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  31. Fornari T, et al. 2015. PLoS One. 10: 0142688. PubMed
  32. Koning B, et al. 2006. Int Immunol. 1.403472222. PubMed
  33. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  34. Johnson KD, et al. 2022. Blood Adv. 6:1464. PubMed
  35. Allegrezza M, et al. 2016. Cancer Res . 76: 6253 - 6265. PubMed
  36. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  37. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  38. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  39. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  40. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  41. Lou F, et al. 2020. STAR Protoc. 1:100115. PubMed
  42. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  43. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  44. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  45. Patnode M, et al. 2013. Glycobiology. 23:381. PubMed
  46. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  47. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  48. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  49. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  50. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  51. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  52. Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed
  53. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  54. Zhang X, et al. 2020. J Immunol. 205:1743. PubMed
  55. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  56. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  57. Ma Y, et al. 2015. J Immunol. 195: 3769 - 3780. PubMed
  58. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  59. Qi X, et al. 2019. Nat Med. 25:1225. PubMed
  60. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  61. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  62. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  63. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  64. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  65. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  66. Skeate JG, et al. 2018. PLoS One. 13:e0191311. PubMed
  67. He L, et al. 2019. iScience. 0.790972222. PubMed
  68. Cheng HW, et al. 2019. Nat Commun. 10:1739. PubMed
  69. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  70. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  71. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  72. Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed
  73. Miki Y, et al. 2016. J Biol Chem. 291: 15588 - 15601. PubMed
  74. Knolle MD et al. 2018. Frontiers in immunology. 1.925 . PubMed
  75. Doonan J, et al. 2019. Nat Commun. 10:1554. PubMed
  76. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  77. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  78. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  79. Yang H, et al. 2022. Nutrients. 14:. PubMed
  80. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  81. Tang CC, et al. 2021. eLife. 10:00. PubMed
  82. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  83. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  84. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  85. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  86. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  87. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  88. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  89. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  90. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  91. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  92. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  93. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  94. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  95. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  96. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  97. Kim SH, et al. 2021. Cell Reports. 35(2):108995. PubMed
  98. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  99. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  100. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  101. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  102. Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed
  103. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  104. Bian G, et al. 2020. British Journal of Pharmacology. 178(3):636-653. PubMed
  105. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  106. Xu M, et al. 2013. J Immunol. 190:5436. PubMed
  107. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  108. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  109. Vacca F, et al. 2020. eLife. 9:e54017.. PubMed
  110. Labiano S, et al. 2017. Oncoimmunology. 6:e1283468. PubMed
  111. Engblom C, et al. 2017. Science. 358:6367. PubMed
  112. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  113. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  114. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  115. Yue W, et al. 2019. Nat Commun. 10:2025. PubMed
  116. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  117. Agrawal M, et al. 2022. Blood. 140:1094. PubMed
  118. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  119. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  120. Lind L, et al. 2021. J Neurovirol. 27:145. PubMed
  121. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  122. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  123. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  124. Lin JC, et al. 2019. Nat Commun. 10:1057. PubMed
  125. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  126. Sánchez-del-Campo L, et al. 2021. J Exp Clin Cancer Res. 40:117. PubMed
  127. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  128. Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed
  129. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  130. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  131. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  132. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  133. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  134. La Salvia S, et al. 2020. Am J Physiol Renal Physiol. 319:F868. PubMed
  135. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  136. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  137. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  138. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  139. Schofield L, et al. 2017. BMC Med. 10.1186/s12916-017-0883-8. PubMed
  140. Oh J, et al. 2021. Clin Cancer Res. 27:4781. PubMed
  141. Harding CL, et al. 2020. Front Cell Infect Microbiol. 10:328. PubMed
  142. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  143. Ma C, et al. 2021. Mol Metab. 47:101170. PubMed
  144. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  145. Sheng J, et al. 2021. eLife. 10:00. PubMed
  146. Zhang S, et al. 2016. PLoS Pathog. 12: 1005617. PubMed
  147. L M, et al. 2016. Brain. 139: 1939-1957. PubMed
  148. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  149. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  150. Kanaya T, et al. 2008. Am J Physiol Gastrointest Liver Physiol. 295:273. PubMed
  151. Hilt ZT, et al. 2019. JCI Insight. 4:5. PubMed
  152. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  153. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  154. Awida Z, et al. 2021. Int J Mol Sci. 23:. PubMed
  155. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  156. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  157. Amatruda M, et al. 2022. Brain Commun. 4:fcac044. PubMed
  158. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
RRID
AB_312670 (BioLegend Cat. No. 100305)
AB_312671 (BioLegend Cat. No. 100306)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account